Focal Gains of VEGFA: Candidate Predictors of Sorafenib Response in Hepatocellular Carcinoma

Josep M. Llovet

doi:10.1016/j.ccr.2014.04.019

Focal Gains of VEGFA: Candidate Predictors of Sorafenib Response in Hepatocellular Carcinoma

Josep M. Llovet

Research output: Contribution to journal › Short survey › peer-review

69 Scopus citations

Abstract

Focal amplifications in 6p21 containing the VEGFA locus occur in 7%-10% of hepatocellular carcinoma (HCC). A recent paper describes how VEGF-A stimulates paracrine secretion of hepatocyte growth factor by stromal cells, which induces tumor progression. HCC patients with VEGFA amplification are distinctly sensitive to sorafenib.

Original language	English
Pages (from-to)	560-562
Number of pages	3
Journal	Cancer Cell
Volume	25
Issue number	5
DOIs	https://doi.org/10.1016/j.ccr.2014.04.019
State	Published - 12 May 2014

Access to Document

10.1016/j.ccr.2014.04.019

Cite this

@article{273974bac20d44da84c07be47cca8e5d,

title = "Focal Gains of VEGFA: Candidate Predictors of Sorafenib Response in Hepatocellular Carcinoma",

abstract = "Focal amplifications in 6p21 containing the VEGFA locus occur in 7\%-10\% of hepatocellular carcinoma (HCC). A recent paper describes how VEGF-A stimulates paracrine secretion of hepatocyte growth factor by stromal cells, which induces tumor progression. HCC patients with VEGFA amplification are distinctly sensitive to sorafenib.",

author = "Llovet, \{Josep M.\}",

note = "Funding Information: J.M.L. has grants from NIH-NIDDK (1R01DK076986-01), National Institute of Health (Spain) I+D Program (SAF-2010-16055), the Samuel Waxman Cancer Research Foundation, the European Commission Framework Programme 7 (Heptromic, proposal number 259744), and the Asociaci{\'o}n Espa{\~n}ola para el Estudio del C{\'a}ncer. ",

year = "2014",

month = may,

day = "12",

doi = "10.1016/j.ccr.2014.04.019",

language = "English",

volume = "25",

pages = "560--562",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - Focal Gains of VEGFA

T2 - Candidate Predictors of Sorafenib Response in Hepatocellular Carcinoma

AU - Llovet, Josep M.

N1 - Funding Information: J.M.L. has grants from NIH-NIDDK (1R01DK076986-01), National Institute of Health (Spain) I+D Program (SAF-2010-16055), the Samuel Waxman Cancer Research Foundation, the European Commission Framework Programme 7 (Heptromic, proposal number 259744), and the Asociación Española para el Estudio del Cáncer.

PY - 2014/5/12

Y1 - 2014/5/12

N2 - Focal amplifications in 6p21 containing the VEGFA locus occur in 7%-10% of hepatocellular carcinoma (HCC). A recent paper describes how VEGF-A stimulates paracrine secretion of hepatocyte growth factor by stromal cells, which induces tumor progression. HCC patients with VEGFA amplification are distinctly sensitive to sorafenib.

AB - Focal amplifications in 6p21 containing the VEGFA locus occur in 7%-10% of hepatocellular carcinoma (HCC). A recent paper describes how VEGF-A stimulates paracrine secretion of hepatocyte growth factor by stromal cells, which induces tumor progression. HCC patients with VEGFA amplification are distinctly sensitive to sorafenib.

UR - https://www.scopus.com/pages/publications/84900320514

U2 - 10.1016/j.ccr.2014.04.019

DO - 10.1016/j.ccr.2014.04.019

M3 - Short survey

C2 - 24823635

AN - SCOPUS:84900320514

SN - 1535-6108

VL - 25

SP - 560

EP - 562

JO - Cancer Cell

JF - Cancer Cell

IS - 5

ER -

Focal Gains of VEGFA: Candidate Predictors of Sorafenib Response in Hepatocellular Carcinoma

Abstract

Access to Document

Fingerprint

Cite this